Clolar, Evoltra(clofarabine)
Clofarabine, Clolar, Evoltra, Ivozall (clofarabine) is a small molecule pharmaceutical. Clofarabine was first approved as Clolar on 2004-12-28. It is used to treat lymphoid leukemia in the USA. It has been approved in Europe to treat precursor cell lymphoblastic leukemia-lymphoma. The pharmaceutical is active against ribonucleoside-diphosphate reductase subunit M2. In addition, it is known to target ribonucleoside-diphosphate reductase large subunit.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| neoplasms | D009369 |
| hemic and lymphatic diseases | D006425 |
| immune system diseases | D007154 |
Trade Name
FDA
EMA
Clofarabine (discontinued: Clofarabine, Clolar)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| clofarabine | ANDA | 2024-02-27 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| lymphoid leukemia | — | D007945 | C91 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| J9027 | Injection, clofarabine, 1 mg |
Clinical
Clinical Trials
183 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Myeloid leukemia acute | D015470 | — | C92.0 | 14 | 21 | 3 | — | — | 33 |
| Leukemia | D007938 | — | C95 | 13 | 17 | 1 | — | — | 25 |
| Myelodysplastic syndromes | D009190 | — | D46 | 10 | 15 | 1 | — | — | 22 |
| Graft vs host disease | D006086 | — | D89.81 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | — | C91.0 | 11 | 8 | — | — | — | 15 |
| Myeloid leukemia | D007951 | — | C92 | 3 | 7 | — | — | — | 8 |
| Neoplasms | D009369 | — | C80 | 7 | 2 | — | — | — | 7 |
| Myelomonocytic leukemia chronic | D015477 | — | C93.1 | 3 | 2 | — | — | — | 4 |
| Preleukemia | D011289 | — | — | 1 | 3 | — | — | — | 4 |
| Non-hodgkin lymphoma | D008228 | — | C85.9 | 4 | 2 | — | — | — | 4 |
| B-cell chronic lymphocytic leukemia | D015451 | — | C91.1 | 4 | 1 | — | — | — | 4 |
| Lymphoid leukemia | D007945 | — | C91 | 3 | 2 | — | — | — | 4 |
| Recurrence | D012008 | — | — | 2 | 2 | — | — | — | 4 |
| Syndrome | D013577 | — | — | — | 3 | — | — | — | 3 |
Show 24 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hematologic neoplasms | D019337 | — | — | 2 | — | — | — | — | 2 |
| Myeloproliferative disorders | D009196 | — | D47.1 | 1 | — | — | — | — | 1 |
| Primary myelofibrosis | D055728 | — | D47.4 | 1 | — | — | — | — | 1 |
| Promyelocytic leukemia acute | D015473 | — | C92.4 | 1 | — | — | — | — | 1 |
| Myelomonocytic leukemia juvenile | D054429 | — | C93.3 | 1 | — | — | — | — | 1 |
| Acute disease | D000208 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Clofarabine |
| INN | clofarabine |
| Description | Clofarabine is a purine nucleoside analogue consisting of a 6-amino-2-chloropurin-9-yl group attached to the 1beta position of 2'-deoxy-2'-fluoro-D-arabinofuranose. It is metabolized intracellularly to the active 5'-triphosphate metabolite, which inhibits DNA synthesisis and so stops the growth of cancer cells. Clofarabine is used as an antimetabolite antineoplastic agent in the treatment of relapsed or refractory acute lymphoblastic leukaemia. It has a role as an antineoplastic agent and an antimetabolite. It is an organofluorine compound and a member of adenosines. |
| Classification | Small molecule |
| Drug class | antineoplastics (arabinofuranosyl derivatives) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F |
Identifiers
| PDB | — |
| CAS-ID | 123318-82-1 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1750 |
| ChEBI ID | 681569 |
| PubChem CID | 119182 |
| DrugBank | DB00631 |
| UNII ID | 762RDY0Y2H (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
PDE8A
PDE8A
Organism
Homo sapiens
Gene name
PDE8A
Gene synonyms
NCBI Gene ID
Protein name
high affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8A
Protein synonyms
cAMP-specific cyclic nucleotide phosphodiesterase 8A
Uniprot ID
Mouse ortholog
Pde8a (18584)
high affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8A (Q059P6)
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 3,085 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
5,318 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use